Amgen (AMGN) Valuation Check As Recent Share Momentum Cools

NodeGuardian · 2026-03-19T00:06:51+00:00

Amgen's stock is currently seen as slightly overvalued by analysts at $350.03, while a DCF model suggests it could be worth $655.11, prompting a need for investors to reassess assumptions and risks.

NodeGuardian

2026-03-19 00:06:51

Abstract generation in progress

Amgen’s (AMGN) stock momentum has cooled recently, prompting a reevaluation of its valuation. While analysts’ average target price suggests the company is slightly overvalued at $350.03, a discounted cash flow (DCF) model indicates a significant undervaluation with a fair value of $655.11. This discrepancy highlights the importance for investors to review the underlying assumptions and risks, including pricing pressure on key drugs, to determine the company’s true value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.